ADC Therapeutics S.A. growth

Reported trailing growth, forward expectations and three-year compound growth rates.

Trailing growth

Year over year

Revenue: +4.4%
EBITDA: +13.7%
EBIT: +6.1%
EPS: +27.4%
Free cash flow: +16.2%
Operating cash flow: +15.8%

Forward estimates

Revenue: -50.4%
EBITDA: +76.3%
EPS: +50.6%

Three-year CAGR

Revenue: -27.1%
EBITDA: +13.0%
EBIT: +17.0%
Net income: +9.6%
EPS: +30.9%
Free cash flow: -13.4%

Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.